Efficacy of Xiidra in Dry Eye Disease After Collagen Cross Linking

Phase 4

• Conditions: Corneal Disease
• Interventions: Drug: Xiidra 5% Ophthalmic Solution

• Registration Number: NCT05045053
• Lead Sponsor: Benha University

Brief Summary

dry eye disease after corneal collagen cross linking affect ocular function leading to reduced vision, photophobia, glare, halos, and foreign body sensation.

Detailed Description

first group of patients were treated with 0.5 % xiidra twice daily and artificial tears for 6 months.Second group treated with artificial tears for 6 months. the treatment starts after corneal collagen cross linking in both groups ,Baseline and post-treatment full ophthalmic examination was done.

Study Timeline

• Study Start: 2021-02-01
• Status Verified: 2021-09
• Study First Submitted: 2021-09-07
• Study First Submitted QC: 2021-09-07
• Last Update Submitted: 2021-09-07
• Study First Posted: 2021-09-16
• Last Update Posted: 2021-09-16
• Primary Completion: 2022-01
• Study Completion: 2022-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• corneal collagen cross linking

Exclusion Criteria

• systemic or ocular diseases ,previous ocular surgery, corneal pathology and contact lens wearers

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
xiidra group	Xiidra 5% Ophthalmic Solution	patients are treated with 0.5 % xiidra twice daily and artificial tears for 6 months after corneal collagen cross linking

Primary Outcome Measures

Name	Time	Method
Change in Break up Time	6 months	fluorescein sodium stripes will be used for measurement of Break up Time in seconds at baseline and during the study

Trial Locations

Locations (1)

INMC; 🇦🇪 Abu Dhabi, United Arab Emirates